West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

WST
West Pharmaceutical Services, Inc.US flagNew York Stock Exchange
316.31
USD
+4.14
- -
22.35BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.66
20.05
19.44
20.59
21.64
23.24
24.86
29.05
38.06
38.8
39.7
39.63
42.52
44.63
Basic EPS, GAAP
1.61
1.79
1.33
1.96
2.04
2.8
3.27
4.68
8.9
7.88
7.99
6.75
6.83
7.52
Free Cash Flow per Basic Share
3.11
2.58
2.95
2.99
3.56
3.91
4.96
6.39
7.85
9.73
10.45
8.95
10.44
9.91
Dividend per Share
0.38
0.41
0.45
0.49
0.53
0.57
0.61
0.65
0.69
0.73
0.77
0.81
0.85
0.86
Book Value per Share
11.82
12.98
13.65
14.87
16.2
18.57
21.19
25.24
33.27
40.41
47.67
54.46
60.77
62.28
Tangible Book Value per Share
10.69
11.37
12.25
13.52
15.57
17.19
19.4
23.18
29.6
34.4
37.11
35.14
42.3
39.82
Basic Weighted Avg Shares
70
71
72
73
74
74
74
74
74
74
74
73
72
72
Sales/Revenue/Turnover
1,368
1,421
1,400
1,509
1,599
1,717
1,840
2,147
2,832
2,887
2,950
2,893
3,074
3,221
Operating Margin (%)
11.83
12.71
12.7
14.91
14.25
14.1
16.24
19.51
26.85
26.35
23.98
20.42
20.69
21.41
Depreciation Expense
85
90
90
91
97
104
103
109
122
121
137
155
171
177
Net Income, GAAP
112
127
96
144
151
207
242
346
662
586
593
493
494
543
Effective Tax Rate (%)
27.33
27.93
22.65
28.66
36.38
17.2
20.22
18.07
14.31
16.87
17.52
18.36
20.24
21.21
Profit Margin (%)
8.21
8.94
6.83
9.52
9.42
12.05
13.14
16.13
23.37
20.3
20.12
17.03
16.06
16.85
Working Capital
414
407
359
401
464
611
717
870
1,148
1,400
1,265
988
1,323
1,153
LT Debt
371
308
229
226
197
196
317
313
272
300
157
284
298
295
Total Equity
906
957
1,024
1,118
1,280
1,396
1,573
1,854
2,335
2,685
2,881
2,682
3,176
2,990
Return on Invested Capital (%)
9.57
10.01
10.41
11.95
10.23
12.99
13.54
16.6
26.48
22.02
18.62
15.43
15.43
17
Return on Capital (%)
10.63
11.34
8.4
11.49
11.48
14.44
14.34
17.26
26.8
19.34
16.75
12.18
10.99
11.88
Return on Common Equity (%)
14.4
14.59
10.05
13.86
13.18
16.11
16.44
20.16
30.49
21.38
18.12
13.11
11.8
12.7

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
21
23
21
LT Borrowings
203
203
203
LT Finance Leases
74
96
92
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
72
71
Market Capitalization
18,993
19,893
18,090

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,823
1,978
1,827
Cash, Cash Equivalents & STI
628
791
521
Accounts Receivable, Net
625
574
686
Inventories
438
444
453
Total Current Liabilities
635
655
674
Payables & Accruals
401
511
450
ST Debt
21
23
21
Deferred Revenue
- -
52
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.3%
11.94%
18.41%
Free Cash Flow
14.33%
10.9%
15.52%
Net Income, GAAP
21.67%
12.84%
0.2%
Sales/Revenue/Turnover
8.53%
8.07%
6.25%
Total Cash Common Dividend
6.59%
4.94%
3.55%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
695
702
747
749
2,893
2025
698
766
805
805
3,074
2026
845
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.52
1.87
1.79
6.75
2025
1.24
1.83
1.94
1.83
6.83
2026
1.93
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.2
0.2
0.21
0.81
2025
0.21
0.21
0.21
0.22
0.85
2026
0.22
- -
- -
- -
- -

Company Description

APIChat
CEO
Eric Green
Full Time Employees
10,600
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
530 Herman O. West Drive Exton PA United States of America 19341-0645
IPO Date
Mar 17, 1980
Business
West Pharmaceutical Services, Inc. is a global manufacturer and provider of integrated containment and delivery systems primarily for injectable drugs and healthcare products. The company's core offerings include stoppers and seals for injectable packaging systems; syringe and cartridge components; self-injection devices featuring patient-centric, connected health technologies; and advanced containment and delivery solutions such as the proprietary Daikyo Crystal Zenith polymer, a high-performance glass alternative suited for sensitive biologics. West also provides contract manufacturing services encompassing injection molding, contract assembly, and finished packaging through facilities in North America and Europe. Founded in 1923, the company is headquartered in Exton, Pennsylvania, and serves pharmaceutical, biologics, vaccine, and consumer healthcare markets worldwide. Recent major strategic developments at West include the launch of the West Synchrony™ Prefillable Syringe System, an innovative, fully verified system-level product designed specifically for biologics and vaccines scheduled for commercial availability in 2026. This system integrates syringe barrel, plunger, and needle components into a harmonized platform that accelerates regulatory submission and enhances supply chain reliability. In addition, West has strengthened its collaboration with Corning Incorporated, combining West’s NovaPure components and Daikyo Flurotec coating technology with Corning’s Valor® Glass and Velocity® Vials to develop advanced pharmaceutical packaging solutions that improve patient safety and drug stability. Furthermore, West has made a strategic investment in Latch Medical, a Dublin-based company specializing in next-generation vaccine and biologics delivery technology focused on intradermal delivery. West operates across more than 50 sites worldwide, including 25 manufacturing locations, supporting its expansive global supply chain. The company reported $2.89 billion in net sales for fiscal year 2024 and is publicly traded on the New York Stock Exchange under the ticker WST. It is also included in the Standard & Poor’s 500 index, reflecting its prominence as a trusted partner to established and emerging drug developers for the safe containment and delivery of life-saving medicines on a global scale. This comprehensive integration of innovative product offerings and strategic partnerships underscores West Pharmaceutical Services’ position as a leader in injectable drug delivery systems, supported by a nearly century-long heritage of technological advancement and manufacturing excellence.

Company News

APIChat
  • West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

  • Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion

  • West Pharma names former Thermo Fisher executive Lagarde as CEO

  • West Appoints Michel Lagarde to be President and Chief Executive Officer

  • A Look at West Pharmaceutical Services Inc (WST) After 3.5% Gain -- GF Value $359.79 vs Price $316.13

  • Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

  • West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast

  • West Pharma says operations recovering after cyberattack

  • West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Investors Await Damage Assessment After West Pharmaceutical Cyberattack

  • ALGN vs. WST: Which Stock Is the Better Value Option?

  • West Pharmaceutical Services, Inc. (WST) Hit a 52 Week High, Can the Run Continue?

  • West Pharmaceutical Services (WST) Just Flashed Golden Cross Signal: Do You Buy?

  • West Pharmaceutical: Multiple Growth Drivers Are A Tailwind

  • West Pharmaceutical Services, Inc. $WST Shares Purchased by Comerica Bank

  • Are You Looking for a Top Momentum Pick? Why West Pharmaceutical Services (WST) is a Great Choice

  • West Pharmaceutical (WST) Upgraded to Strong Buy: Here's What You Should Know

  • Best Momentum Stocks to Buy for April 29th

  • From Slide to Surge: How West Pharmaceutical Services Reclaimed Its Mojo in 2026

  • West to Participate in Upcoming Investor Conferences